Clinical Trial Update: ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3 [Phase 3]

View source ↗

Summary

Milestone Pharmaceuticals' Phase 3 trial ReVeRA-301 evaluating etripamil for atrial fibrillation is currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Etripamil (etripamil)

Snippet

Sponsor: Milestone Pharmaceuticals Inc. | Conditions: Atrial Fibrillation | Phase 3 | Status: NOT_YET_RECRUITING